Inotiv, Inc. and eighteen affiliated debtors filed voluntary petitions on June 3, 2026, in the United States Bankruptcy Court for the Southern District of Texas. The filing is not a search for a buyer or a runway to fix operations. It is the execution step of a deal that was already negotiated and documented before the petition. A Restructuring Support Agreement signed the day before filing carries the consent of more than 99% of first-lien claims, more than 85% of the PIK Notes, and more than 80% of the unsecured convertible notes.

That level of prepetition agreement is what makes the rest of the plan possible. The debtors propose to confirm the plan at a combined hearing on July 14, roughly six weeks after the June 3 petition, with an effective date no later than July 23. The headline metrics frame the problem the deal is built to solve and the shape of the solution.

Inotiv is an Indiana-based contract research organization operating in two segments. Its Discovery and Safety Assessment segment provides nonclinical drug discovery and development services, including pharmacokinetic and pharmacodynamic analysis, toxicology, safety pharmacology, and bioanalytical testing. Its Research Models and Services segment supplies purpose-bred laboratory animals, including rodents and non-human primates, for biomedical research. The company runs 24 owned or leased facilities across 22 locations in four countries, with roughly 86% of facilities in the United States, and employs approximately 1,756 people. For the six months ended March 31, 2026, it reported total revenue of approximately $238.5 million against total assets of approximately $702.4 million. The shares trade on Nasdaq under the ticker NOTV, and the disclosure statement contemplates that the reorganized parent would emerge as a private company.

The distress traces directly to a growth strategy. Between July 2018 and July 2022, the company completed fourteen acquisitions in roughly 48 months. The largest was the November 2021 purchase of Envigo RMS Holding Corp., which built out the Research Models and Services segment and was funded in part through the secured credit agreement entered into the same day. The acquisitions delivered scale. They also delivered leverage that the business could not carry once revenue softened.

By the petition date the company held approximately $488.7 million of funded debt at a weighted average effective rate above 11.6%. Interest expense alone reached approximately $27.5 million for the six months ended March 31, 2026. That cost ran against a declining top line, with Research Models and Services revenue down approximately $12.6 million, or 8.0%, year over year, and an operating loss of approximately $35.6 million for the same six-month period. A balance sheet assembled for expansion was now servicing debt the operations could no longer support.

Leverage made the company fragile. A set of concurrent industry pressures, each documented in the supporting declaration, is what turned fragility into a filing. They compound rather than substitute for one another.

These pressures compounded an already leveraged balance sheet. The two first-lien tranches matured within months of the petition, on October 15 and November 5, 2026, and the company could not refinance that wall of maturities as it came due.

The funded debt resolves into five tranches of descending priority. The structure matters because it determines who controls the case and where recoveries stop.

The maturity wall is the trigger, but the liquidity position is what forced the calendar. On the petition date the debtors held approximately $2.7 million in unrestricted cash against weekly operating disbursements of approximately $8.0 million. A business spending eight dollars for every three it holds cannot wait. That gap is the reason the first day of the case includes an emergency request for debtor-in-possession financing, and the reason the interim order is sought within three days of filing.

Perella Weinberg Partners valued the debtors using a discounted cash flow analysis, a comparable public companies analysis, and a precedent transactions analysis. The work produces an enterprise value range of $222 million to $273 million, with a midpoint of $247 million, and an implied equity value range of $77 million to $128 million, with a midpoint of $102 million, on an assumed effective date of July 17, 2026.

The valuation does two jobs in this case. It locates the value break inside the first-lien class, because $274.9 million of first-lien claims exceeds the top of the enterprise value range. And it sets the predicate for the plan's treatment of junior creditors, who receive value only because senior creditors agree to share it. With first-lien claims sitting above total enterprise value, the proposed equity allocation puts the overwhelming majority of the reorganized company in first-lien hands.

The reorganized company would carry $150 million of exit debt against a midpoint enterprise value of $247 million, a leverage ratio of roughly 0.6 times. That is a structural reset from the pre-filing position, where funded debt sat at roughly 2.0 times enterprise value.

The debtor-in-possession facility is a superpriority, priming term loan totaling $65,515,451. It splits into $25 million of new money, of which up to $16 million is available on the interim order, and a $40,515,451 cashless roll-up of the existing Bridge Facility delayed-draw loans. The agent is Acquiom Agency Services LLC.

The defining feature is the conversion mechanism. All DIP claims convert dollar for dollar into the $150 million Exit Term Loan Facility on the effective date. The DIP lenders are therefore repaid not in cash but by stepping into the reorganized company's senior debt, which removes the refinancing risk that often shadows an exit. The portion of the $150 million facility not consumed by the converted DIP claims, the remaining exit term loans, flows to first-lien claimholders as part of their recovery. That is why first-lien holders receive both 93% of the new equity and a slice of the exit debt, and why they have every incentive to support the plan.

Establishing the Arm's-Length Character

Because the facility comes from existing lenders and includes a roll-up, the debtors built a record showing it was the best financing available. The marketing process is the evidence that the "unable to obtain credit" requirement of Section 364 is satisfied.

Eleven third-party DIP lenders were solicited specifically, and none was willing to lend on terms the debtors found acceptable. The roll-up of the $40.5 million Bridge Facility is justified on the standard ground that the prepetition secured parties would not consent to the use of their cash collateral without it. The motion frames authorization under the business judgment standard, citing the familiar line of DIP-financing authority, and notes that there is no duty to canvass every possible lender.

The plan equitizes the funded debt and reinstates the obligations the business needs to keep operating. The proposed recoveries follow the value break. First-lien holders receive nearly all of the new equity, junior funded creditors receive a small negotiated allocation, and existing equity is cancelled.

The "Notes Recovery" is defined as 7% of the new equity interests on a fully diluted basis, subject to dilution, plus the new warrants. The new warrants are exercisable into equity representing 11% of the equity issued on the effective date over a four-year window. A management incentive plan reserves up to 10% of fully diluted equity, to be set by the new board after emergence.

A prepackaged plan only works if the business survives the case intact. Two first-day motions do most of that work, and they connect directly to the plan's treatment of general unsecured creditors.

The trade claims motion seeks authority to pay approximately $20.2 million of prepetition trade claims, spanning model procurement and care vendors, medical supplies, lienholders, professional services, and other trade creditors. It also addresses customer prepayment programs, roughly $23 million of advance billing arrangements in the Discovery segment and roughly $18 million of client deposits in the Research Models segment, which the debtors argue they must continue honoring to protect an approximately $151.8 million services backlog. The employee wages motion seeks roughly $4.45 million for a workforce of approximately 1,756 employees whose scientific expertise is the asset that produces the company's value.

Paying these creditors in full at the outset is what renders Class 7 unimpaired. An unimpaired class is deemed to accept and does not vote, which removes general unsecured creditors as a source of confirmation risk and keeps the case clean. The operational logic and the confirmation logic point in the same direction.

Three filings address risks that could erode value or complicate the releases, and they reward attention because they reveal where the deal could still be contested.

Preserving $303.3 Million of Tax Attributes

The equity transfer restrictions motion seeks to protect approximately $303.3 million in tax attributes, comprising roughly $48.8 million of federal net operating losses, roughly $125.1 million of Section 163(j) interest carryforwards, and roughly $129.4 million of state net operating loss carryovers. The mechanism designates any holder of 4.5% or more of common shares a substantial shareholder subject to notice requirements, and renders void any transfer that would trigger an ownership change under Section 382. Equity is being cancelled under the plan, but the attributes survive to benefit the reorganized entity, and an ownership change before emergence could sharply limit their usable value.

Extending the Stay to the CEO

The debtors seek to extend the automatic stay to the President and CEO, the individual defendant in a fraud complaint filed in Florida state court on May 11, 2026, weeks before the petition. The claims arise from communications about a September 2024 financing transaction involving convertible debt securities. The argument is that the company's indemnification obligation makes any judgment against the CEO effectively a judgment against the estate, which supports extending the stay to the non-debtor defendant.

The plan was solicited before the petition under the prepackaged provisions of the Bankruptcy Code, which is what allows a combined hearing on disclosure statement approval and confirmation. The only classes requiring nonconsensual confirmation are the deemed-rejecting equity and subordinated-claim classes, and because they are clearly out of the money, the absolute priority rule and the best interests test are satisfied without difficulty. The work, then, is calendar management against the milestones the Restructuring Support Agreement imposes.

The deal is documented and broadly supported, but it is not yet confirmed, and several variables could still affect the path to emergence.

The Calendar Is the Risk

The expedited timeline leaves little margin. The plan is set for confirmation at a combined hearing 41 days after filing, with an effective date no later than 50 days out, and the objection deadline allows roughly 33 days from filing for parties to review and challenge the plan. The RSA milestones are hard deadlines, and a missed milestone can trigger termination rights. Court scheduling or any contested matter could compress an already tight runway.

The Liquidation Test Favors the Plan

The disclosure statement's liquidation analysis estimates gross distributable value in a Chapter 7 of $88.1 million to $131.2 million, well below the going-concern enterprise value. Every class fares at least as well under the plan, and most fare materially better. The comparison is the backbone of the best interests showing.

Ongoing Obligations and Litigation

The reinstated DOJ claims carry continuing fine payments through June 2028 and a compliance monitorship through at least January 2028, obligations the reorganized entity inherits. The fraud complaint against the CEO, tied to the same September 2024 financing that created the PIK Notes, sits alongside the special committee's investigation. If those claims have merit, they could touch the releases, the committee's determinations, and the treatment of the PIK Notes themselves.

Taken as a whole, the Inotiv filing is a coordinated prepackaged restructuring that preserves going-concern value, keeps trade creditors and employees whole, and delivers the company to its senior secured lenders through equitization. The open question is execution: whether the debtors can hold the expedited RSA calendar while managing potential objections from out-of-the-money equity holders, any concerns the U.S. Trustee raises about the pace or the scope of releases, and the loose thread of the special committee's investigation.